December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Photographic And Fluorescein Angiographic Outcomes From The Intravitreal Triamcinolone Study For Neovascular Armd
Author Affiliations & Notes
  • MC Gillies
    Ophthalmology
    University of Sydney Sydney Australia
  • W Chua
    Ophthalmology
    University of Sydney Sydney Australia
  • P Mitchell
    Ophthalmology
    University of Sydney Sydney Australia
  • F Billson
    Ophthalmology
    University of Sydney Sydney Australia
  • A Hunyor
    Ophthalmology
    University of Sydney Sydney Australia
  • P Penfold
    Ophthalmology
    University of Sydney Sydney Australia
  • J Simpson
    Public Health and Community Medicine
    University of Sydney Sydney Australia
  • Footnotes
    Commercial Relationships    M.C. Gillies, Eyecare Med P; Eyecare Med P; W. Chua, None; P. Mitchell, None; F. Billson, Eyecare Med P; A. Hunyor, None; P. Penfold, Eyecare med P; J. Simpson, None. Grant Identification: Australian NHMRC
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2907. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MC Gillies, W Chua, P Mitchell, F Billson, A Hunyor, P Penfold, J Simpson; Photographic And Fluorescein Angiographic Outcomes From The Intravitreal Triamcinolone Study For Neovascular Armd . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2907.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To assess the photographic and fluorescein angiographic changes in patients with exudative age-related macular degeneration treated with a single injection of intravitreal triamcinolone 4mg. Methods:The Intravitreal Triamcinolone Study is a prospective, single centred, double-blind, placebo-controlled, randomised clinical trial. Fundus photographs and angiograms taken at baseline, 3 months (FA), 6 months (photos), and 12 months were graded in a masked fashion according to a standardised protocol. Specific parameters graded on photographs included neurosensory detachment, RPE detachment, retinal haemorrhage, hard exudates, subretinal fibrosis, geographic atrophy, and presence of triamcinolone crystals. Features graded on angiograms included CNV type (classic/occult), CNV location (sub/juxta/extrafoveal), CNV size, and fluorescein leakage. Results:151 eyes of 139 patients were enrolled in the study. Baseline CNV characteristics were similar between the treatment and placebo groups. At 3 months, in the treatment group, CNV size had increased in 28 eyes (37%), remained unchanged in 19 (25%), and decreased in 6 (8%). This compares with 35 (46%) increased, 14 (18%) unchanged, and 0 decreased in the placebo group (P=0.008). A significant difference in favour of the treatment group was also found in the size of the neurosensory detachment at 6 months. No difference was found between the two groups with respect to any of the other parameters. Conclusion:Intravitreal triamcinolone appears to inhibit the growth of CNV and reduces subretinal fluid in the short term. Whilst this does not support its use as a sole agent in the treatment of classic CNV, it suggests that intravitreal triamcinolone should be investigated for more refined indications, for example for less advanced forms of the disease or in conjunction with other treatment.

Keywords: 308 age-related macular degeneration • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 430 imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×